This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols

被引:35
作者
Schiavone, Francesca [1 ,2 ]
Bathia, Riya [1 ,2 ]
Letchemanan, Krishna [1 ,2 ]
Masters, Lindsey [1 ,2 ]
Amos, Claire [1 ,2 ]
Bara, Anna [1 ,2 ]
Brown, Louise [1 ,2 ]
Gilson, Clare [1 ,2 ]
Pugh, Cheryl [1 ,2 ]
Atako, Nafisah [1 ,2 ]
Hudson, Fleur [1 ,2 ]
Parmar, Mahesh [1 ,2 ]
Langley, Ruth [1 ,2 ]
Kaplan, Richard S. [1 ,2 ]
Parker, Chris [3 ,4 ]
Attard, Gert [5 ]
Clarke, Noel W. [6 ]
Gillessen, Silke [7 ,8 ,9 ]
James, Nicholas D. [10 ]
Maughan, Tim [11 ]
Sydes, Matthew R. [1 ,2 ]
机构
[1] UCL, MRC Clin Trials Unit UCL, Inst Clin Trials & Methodol, 90 High Holborn, London WC1V 6LJ, England
[2] MRC London Hub Trials Methodol Res, London, England
[3] Inst Canc Res, Sutton, Surrey, England
[4] Royal Marsden Hosp, Sutton, Surrey, England
[5] UCL, UCL Canc Inst, London, England
[6] Christie & Royal Salford Hosp, Manchester, Lancs, England
[7] Univ Manchester, Div Canc Sci, Manchester, Lancs, England
[8] Christie, Manchester, Lancs, England
[9] Kantonsspital St Gallen, St Gallen, Switzerland
[10] Univ Birmingham, Inst Canc & Genom Sci, Birmingham, W Midlands, England
[11] Univ Oxford, Canc Res UK MRC Oxford Inst Radiat Oncol, Oxford, England
基金
英国医学研究理事会;
关键词
Adaptive trials; Platform; Multi-arm multi stage; Protocol; Trial conduct; Trial management; CLINICAL-TRIALS; MULTIARM; THERAPY; CANCER;
D O I
10.1186/s13063-019-3216-8
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
BackgroundThere are limited research and literature on the trial management challenges encountered in running adaptive platform trials. This trial design allows both (1) the seamless addition of new research comparisons when compelling clinical and scientific research questions emerge, and (2) early stopping of accrual to individual comparisons that do not show sufficient activity without affecting other active comparisons. Adaptive platform design trials also offer many potential benefits over traditional trials, from faster time to accrual to contemporaneously recruiting multiple research comparisons, added flexibility to focus on more promising research comparisons via pre-planned interim analyses and potentially shorter time to primary results. We share here our experiences from a trial management perspective, highlighting the challenges and successes.MethodsWe evaluated the operational aspects of making changes to these adaptive platform trials and identified both common and trial-specific challenges. The operational steps and challenges linked to both the addition of new research comparisons and stopping recruitment following pre-planned interim analysis were considered in our evaluation.ResultsSpecific operational challenges in these adaptive platform protocols, additional to those in traditional two-arm trials, were identified. Key lessons are presented describing some of the solutions and considerations over conducting these trials.Careful consideration on the practicality of the protocol structure (modular versus single protocol), the longevity and continuity of trial oversight committees, and having clear clinical and scientific criteria for the addition of new research comparisons were identified as some of the most common challenges.ConclusionsUnderstanding the operational complexities associated with running adaptive platform protocols is paramount for their conduct, adaptive platform trials offer an efficient model to run randomised controlled trials and we are continuing to work to reduce further the effort required from an operational perspective.Trial registrationFOCUS4: ISRCTN Registry, ISRCTN90061546. Registered on 16 October 2013. STAMPEDE: ISRCTN Registry, ISRCTN78818544. Registered on 2 February 2004.
引用
收藏
页数:13
相关论文
共 20 条
  • [1] Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial
    Adams, Richard
    Brown, Ewan
    Brown, Louise
    Butler, Rachel
    Falk, Stephen
    Fisher, David
    Kaplan, Richard
    Quirke, Phil
    Richman, Susan
    Samuel, Leslie
    Seligmann, Jenny
    Seymour, Matt
    Shiu, Kai Keen
    Wasan, Harpreet
    Wilson, Richard
    Maughan, Tim
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (03) : 162 - 171
  • [2] Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial
    Attard, Gerhardt
    Sydes, Matthew R.
    Mason, Malcolm D.
    Clarke, Noel W.
    Aebersold, Daniel
    de Bono, Johann S.
    Dearnaley, David P.
    Parker, Chris C.
    Ritchie, Alastair W. S.
    Russell, J. Martin
    Thalmann, George
    Cassoly, Estelle
    Millman, Robin
    Matheson, David
    Schiavone, Francesca
    Spears, Melissa R.
    Parmar, Mahesh K. B.
    James, Nicholas D.
    [J]. EUROPEAN UROLOGY, 2014, 66 (05) : 799 - 802
  • [3] Measuring the impact of methodological research: a framework and methods to identify evidence of impact
    Brueton, Valerie C.
    Vale, Claire L.
    Choodari-Oskooei, Babak
    Jinks, Rachel
    Tierney, Jayne F.
    [J]. TRIALS, 2014, 15
  • [4] SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
    Chan, An-Wen
    Tetzlaff, Jennifer M.
    Altman, Douglas G.
    Laupacis, Andreas
    Gotzsche, Peter C.
    Krleza-Jeric, Karmela
    Hrobjartsson, Asbjorn
    Mann, Howard
    Dickersin, Kay
    Berlin, Jesse A.
    Dore, Caroline J.
    Parulekar, Wendy R.
    Summerskill, William S. M.
    Groves, Trish
    Schulz, Kenneth F.
    Sox, Harold C.
    Rockhold, Frank W.
    Rennie, Drummond
    Moher, David
    [J]. ANNALS OF INTERNAL MEDICINE, 2013, 158 (03) : 200 - +
  • [5] Gilbert DC, 2018, BJU INT
  • [6] Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform
    Gillessen, Silke
    Gilson, Clare
    James, Nick
    Adler, Amanda
    Sydes, Matthew R.
    Clarke, Noel
    [J]. EUROPEAN UROLOGY, 2016, 70 (06) : 906 - 908
  • [7] Grant AM, 2005, LANCET, V365, P711
  • [8] Adaptive designs undertaken in clinical research: a review of registered clinical trials
    Hatfield, Isabella
    Allison, Annabel
    Flight, Laura
    Julious, Steven A.
    Dimairo, Munyaradzi
    [J]. TRIALS, 2016, 17
  • [9] Hearn J, 2011, TRIALS, V12, pA6, DOI [10.1186/1745-6215-12-S1-A6, DOI 10.1186/1745-6215-12-S1-A6]
  • [10] Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
    James, Nicholas D.
    Sydes, Matthew R.
    Clarke, Noel W.
    Mason, Malcolm D.
    Dearnaley, David P.
    Spears, Melissa R.
    Ritchie, Alastair W. S.
    Parker, Christopher C.
    Russell, J. Martin
    Attard, Gerhardt
    de Bono, Johann
    Cross, William
    Jones, Rob J.
    Thalmann, George
    Amos, Claire
    Matheson, David
    Millman, Robin
    Alzouebi, Mymoona
    Beesley, Sharon
    Birtle, Alison J.
    Brock, Susannah
    Cathomas, Richard
    Chakraborti, Prabir
    Chowdhury, Simon
    Cook, Audrey
    Elliott, Tony
    Gale, Joanna
    Gibbs, Stephanie
    Graham, John D.
    Hetherington, John
    Hughes, Robert
    Laing, Robert
    McKinna, Fiona
    McLaren, Duncan B.
    O'Sullivan, Joe M.
    Parikh, Omi
    Peedell, Clive
    Protheroe, Andrew
    Robinson, Angus J.
    Srihari, Narayanan
    Srinivasan, Rajaguru
    Staffurth, John
    Sundar, Santhanam
    Tolan, Shaun
    Tsang, David
    Wagstaff, John
    Parmar, Mahesh K. B.
    [J]. LANCET, 2016, 387 (10024) : 1163 - 1177